Teva Shifts to Direct NYSE Listing, Bolstering Growth Strategy
Event summary
- Teva's ordinary shares began trading directly on the NYSE on September 14, 2026, replacing its ADS program.
- The company's three flagship innovative brands—AUSTEDO®, AJOVY®, and UZEDY®—grew collectively by over 40% year-over-year.
- Teva expects 2026 revenues of approximately $3.7 billion from these brands.
- The company has achieved investment-grade credit ratings from all three major ratings agencies.
The big picture
Teva's shift to a direct NYSE listing underscores its strategic pivot toward growth, leveraging a robust innovative medicines portfolio and a leading generics business. This move aligns with broader industry trends of biopharmaceutical companies seeking to strengthen their financial foundations and expand investor access. The company's recent achievement of investment-grade credit ratings further solidifies its position as it aims to create long-term shareholder value.
What we're watching
- Execution Risk
- How Teva will sustain the momentum of its innovative medicines portfolio amid competitive pressures.
- Market Positioning
- Whether the direct NYSE listing will enhance Teva's access to U.S. capital markets and attract new investors.
- Financial Discipline
- The pace at which Teva can continue reducing debt while investing in long-term growth.
Related topics